Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) derivative of phenylacetic acid, which elicits its therapeutic effects via inhibition of cyclooxygenase (Ortiz, 2017; Patrignani & Patrono, 2015). Diclofenac is globally used by millions of people mainly for the treatment of pain, inflammation, degenerative joint disease, rheumatoid arthritis, dysmenorrhoea and trauma (Ahmed et al., 2019; Aygun, Kaplan, Odaci, Onger, & Altunkaynak, 2012). Indeed, global diclofenac consumed yearly has been estimated to be approximately 940 tons (Zhang, Geissen, & Gal, 2008). Although diclofenac is an effective chemotherapeutic drug, its harmful effects in both animals and humans are associated with inhibition of prostaglandin biosynthesis. Specifically, diclofenac-mediated nephropathy, hepatotoxicity and ulceration, which are well-documented, have been related to the induction of oxidative damage (Ahmed, Gad, & El-Raouf, 2017;